{"id":"W2906404816","doi":"10.1016/j.jval.2018.09.219","title":"PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Sunitinib; Ipilimumab; Nivolumab; Cost-effectiveness analysis; Oncology; Internal medicine; Renal cell carcinoma; Population; Clinical trial; Discontinuation; Cancer; Cost effectiveness; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003769052,0.001046324,0.002339135,0.001323171,0.0007027016,0.002110343,0.001525404,0.0009744407,0.002655329],"category_scores_gemma":[0.008885445,0.000608206,0.004761995,0.002628531,0.0008058022,0.000666614,0.0007773978,0.00173487,0.0001393488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.06403001,"about_ca_system_score_gemma":0.04344498,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.902244,"about_ca_topic_score_gemma":0.8964954,"domain_scores_codex":[0.9964811,0.00157038,0.0002052357,0.0002637576,0.0008053549,0.0006740965],"domain_scores_gemma":[0.9967062,0.001236909,0.0004876967,0.0001055353,0.0008012948,0.0006623029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.2262119,0.005833056,0.1389097,0.009071983,0.04520332,0.001596394,0.0004352754,0.3875582,0.004367988,0.006493739,0.01366187,0.1606566],"study_design_scores_gemma":[0.07379931,0.03209937,0.4290421,0.002397396,0.06734671,0.001229673,0.001665128,0.3667565,0.002661234,0.002502048,0.01993863,0.0005618717],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739603,0.0117126,0.0007303976,0.001655984,0.0001104764,0.0008686215,0.00653577,0.00003896756,0.004386747],"genre_scores_gemma":[0.9950349,0.001770511,0.0005318812,0.0001426019,0.00002335127,0.00008373233,0.001778863,0.000007223656,0.0006268959],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09775603,"threshold_uncertainty_score":0.4645724,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2287421618054987,"score_gpt":0.3873366656431198,"score_spread":0.1585945038376211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}